The Whitefield planning group : Whitefield Eco-Industrial Park : Whitefield, NH

The Whitefield Planning Group is a collaboration of key stakeholders concerned with the development of the and the effort to develop the Whitefield Industrial Park in New Hampshire (US). The thesis describes how the start-up phase of the collaboration and the desired goals for economic development for this area in the White Mountains region of the state. (Library-derived description)Corey, P.L. (2002). The Whitefield planning group: Whitefield Eco-Industrial Park: Whitefield, NH. Retrieved from http://academicarchive.snhu.eduMaster of Science (M.S.)School of Community Economic Developmen

Characterization and cloning of fasciclin I and fasciclin II glycoproteins in the grasshopper

Monoclonal antibodies were previously used to identify two glycoproteins, called fasciclin I and II (70 and 95 kDa, respectively), which are expressed on different subsets of axon fascicles in the grasshopper (Schistocerca americana) embryo. Here the monoclonal antibodies were used to purify these two membrane-associated glycoproteins for further characterization. Fasciclin II appears to be an integral membrane protein, where fasciclin I is an extrinsic membrane protein. The amino acid sequences of the amino terminus and fragments of both proteins were determined. Using synthetic oligonucleotide probes and antibody screening, we isolated genomic and cDNA clones. Partial DNA sequences of these clones indicate that they encode fasciclins I and II

Building inclusive and welcoming student health centers for transgender students

INTRODUCTION: While health, wellness, and healthcare are essential to every human being, not much is known about the health and healthcare experiences of transgender students on college campuses. Understanding these healthcare experiences are important because when we recognize them, we can establish a healthy relationship of trust. There is a growing number of transgender students on West Chester University campus, who felt they were not getting the appropriate support and care. As a result, a project was started at student health services to help transgender students effectively access sensitive and welcoming care and support. METHODS: To address the needs of the transgender student population and improve the model of care at student health services, gaining a better understanding of the transgender community was a vital step. To become familiarized with their needs and health concerns, a Likert survey was created and disseminated to investigate the current issues regarding barriers of adequate care. Additionally, to identify the barriers of providing adequate care, student and health professional interviews were completed. The students involved in the interviews and questionnaires were recruited through LGBTQ Support Services Center on West Chester University’s campus. A needs assessment was also created to gain a better understanding of the health needs of the transgender student community. The available resources and services provided to the LGBTQ students at West Chester University were reviewed and compared to other colleges and universities. RESULTS: Students expressed that they felt the healthcare providers were underprepared to provide care and that their care could be improved upon. Through meeting with students and clinicians, a key barrier was the unfamiliarity with transgender health and in addressing transgender-specific health needs. It was also discovered that being unprepared to provide care, resulted in unconscious and implicit bias and the perpetuation of transgender exclusive practices. DISCUSSION: This project identified themes, barriers and areas of concern expressed by transgender students. By identifying these elements, further research can be conducted to better understand student’s perceptions and feelings when seeking healthcare, and whether these experiences impact health outcomes. The purpose of this project was to create an atmosphere geared towards providing healthcare services that are inclusive to all people of all gender identities. With the growing number of transgender students on college campuses, establishing welcoming health setting for students is very important

The Hera orebody: a complex distal (Au–Zn–Pb–Ag–Cu) skarn in the Cobar Basin of central New South Wales, Australia

The Hera Au–Pb–Zn–Ag deposit in the southeastern Cobar Basin of central New South Wales preserves calc-silicate veins and remnant sandstone/carbonate-hosted skarn within a reduced anchizonal Siluro-Devonian turbidite sequence. The skarn orebody distribution is controlled by a long-lived, basin margin fault system, that has intersected a sedimentary horizon dominated by siliciclastic turbidite, with lesser gritstone and thick sandstone intervals, and rare carbonate-bearing stratigraphy. Foliation (S1) envelopes the orebody and is crosscut by a series of late-stage east–west and north–south trending faults. Skarn at Hera displays mineralogical zonation along strike, from southern spessartine–grossular–biotite–actinolite-rich associations, to central diopside-rich–zoisite–actinolite/tremolite–grossular-bearing associations, through to the northern most tremolite–anorthite-rich (garnet-absent) association in remnant carbonate-bearing lithologies and sandstone horizons; the northern lodes also display zonation down dip to garnet present associations. High-T, prograde skarn assemblages rich in pyroxene and garnet are pervasively replaced by actinolite/tremolite–biotite-rich retrograde skarn which coincides with the main pulse of sulfide mineralization. The dominant sulfides are high-Fe–Mn sphalerite–galena–non-magnetic high-Fe pyrrhotite–chalcopyrite; pyrite, arsenopyrite; scheelite (low Mo) is locally abundant. The distribution of metals in part mimics the changing gangue mineralogy, with Au concentrated in the southern and lower northern lode systems and broadly inverse concentrations for Ag–Pb–Zn. Stable isotope data (O–H–S) from skarn amphiboles and associated sulfides are consistent with magmatic (or metamorphic) water and sulfur input during the retrograde skarn phase, while hydrosilicates and sulfides from the wall rocks display comparatively elevated δD and mixed δ34S consistent with progressive mixing or dilution of original magmatic (or metamorphic) waters within the Hera deposit by unexchanged waters typical of low latitude (tropical) meteoritic waters. High precision titanite (U–Pb) and biotite (Ar–Ar) geochronology reveals a manifold orebody commencing with high-T skarn and retrograde Pb–Zn-rich skarn formation at ≥403 Ma, Au–low-Fe sphalerite mineralization at 403.4 ± 1.1 Ma, foliation development remobilization or new mineralization at 390 ± 0.2 Ma followed by thrusting, orebody dismemberment at 384.8 ± 1.1 Ma and remobilization or new mineralization at 381.0 ± 2.2 Ma. The polymetallic nature of the Hera orebody is a result of multiple mineralization events during extension and compression and involving both magmatic and likely formational metal sources

Targeting the HSP60/10 chaperonin systems of Trypanosoma brucei as a strategy for treating African sleeping sickness

Trypanosoma brucei are protozoan parasites that cause African sleeping sickness in humans (also known as Human African Trypanosomiasis—HAT). Without treatment, T. brucei infections are fatal. There is an urgent need for new therapeutic strategies as current drugs are toxic, have complex treatment regimens, and are becoming less effective owing to rising antibiotic resistance in parasites. We hypothesize that targeting the HSP60/10 chaperonin systems in T. brucei is a viable anti-trypanosomal strategy as parasites rely on these stress response elements for their development and survival. We recently discovered several hundred inhibitors of the prototypical HSP60/10 chaperonin system from Escherichia coli, termed GroEL/ES. One of the most potent GroEL/ES inhibitors we discovered was compound 1. While examining the PubChem database, we found that a related analog, 2e-p, exhibited cytotoxicity to Leishmania major promastigotes, which are trypanosomatids highly related to Trypanosoma brucei. Through initial counter-screening, we found that compounds 1 and 2e-p were also cytotoxic to Trypanosoma brucei parasites (EC50 = 7.9 and 3.1 μM, respectively). These encouraging initial results prompted us to develop a library of inhibitor analogs and examine their anti-parasitic potential in vitro. Of the 49 new chaperonin inhibitors developed, 39% exhibit greater cytotoxicity to T. brucei parasites than parent compound 1. While many analogs exhibit moderate cytotoxicity to human liver and kidney cells, we identified molecular substructures to pursue for further medicinal chemistry optimization to increase the therapeutic windows of this novel class of chaperonin-targeting anti-parasitic candidates. An intriguing finding from this study is that suramin, the first-line drug for treating early stage T. brucei infections, is also a potent inhibitor of GroEL/ES and HSP60/10 chaperonin systems

Long QT Syndrome Type 2: Emerging Strategies for Correcting Class 2 \u3cem\u3eKCNH2 (hERG)\u3c/em\u3e Mutations and Identifying New Patients

Significant advances in our understanding of the molecular mechanisms that cause congenital long QT syndrome (LQTS) have been made. A wide variety of experimental approaches, including heterologous expression of mutant ion channel proteins and the use of inducible pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) from LQTS patients offer insights into etiology and new therapeutic strategies. This review briefly discusses the major molecular mechanisms underlying LQTS type 2 (LQT2), which is caused by loss-of-function (LOF) mutations in the KCNH2 gene (also known as the human ether-à-go-go-related gene or hERG). Almost half of suspected LQT2-causing mutations are missense mutations, and functional studies suggest that about 90% of these mutations disrupt the intracellular transport, or trafficking, of the KCNH2-encoded Kv11.1 channel protein to the cell surface membrane. In this review, we discuss emerging strategies that improve the trafficking and functional expression of trafficking-deficient LQT2 Kv11.1 channel proteins to the cell surface membrane and how new insights into the structure of the Kv11.1 channel protein will lead to computational approaches that identify which KCNH2 missense variants confer a high-risk for LQT2

Maternal and Child Sexual Abuse History: An Intergenerational Exploration of Children’s Adjustment and Maternal Trauma-Reflective Functioning

Objective: The aim of the current study was to investigate associations, unique and interactive, between mothers’ and children’s histories of childhood sexual abuse (CSA) and children’s psychiatric outcomes using an intergenerational perspective. Further, we were particularly interested in examining whether maternal reflective functioning about their own trauma (T-RF) was associated with a lower likelihood of children’s abuse exposure (among children of CSA-exposed mothers).Methods: One hundred and eleven children (Mage = 9.53 years; 43 sexual abuse victims) and their mothers (Mage = 37.99; 63 sexual abuse victims) participated in this study. Mothers completed the Parent Development Interview (PDI), which yielded assessments of RF regarding their own experiences of abuse, and also reported on their children’s internalizing and externalizing symptoms.Results: Children of CSA-exposed mothers were more likely to have experienced CSA. A key result was that among CSA-exposed mothers, higher maternal T-RF regarding their own abuse was associated with lower likelihood of child CSA-exposure. Mothers’ and children’s CSA histories predicted children’s internalizing and externalizing symptoms, such that CSA exposure for mother or child was associated with greater symptomatology in children.Conclusion: The findings show that the presence of either maternal or child CSA is associated with more child psychological difficulties. Importantly in terms of identifying potential protective factors, maternal T-RF is associated with lower likelihood of CSA exposure in children of CSA-exposed mothers. We discuss these findings in the context of the need for treatments focusing on increasing T-RF in mothers and children in the context of abuse to facilitate adaptation and reduce the intergenerational risk

LINCS Canvas Browser: interactive web app to query, browse and interrogate LINCS L1000 gene expression signatures

For the Library of Integrated Network-based Cellular Signatures (LINCS) project many gene expression signatures using the L1000 technology have been produced. The L1000 technology is a cost-effective method to profile gene expression in large scale. LINCS Canvas Browser (LCB) is an interactive HTML5 web-based software application that facilitates querying, browsing and interrogating many of the currently available LINCS L1000 data. LCB implements two compacted layered canvases, one to visualize clustered L1000 expression data, and the other to display enrichment analysis results using 30 different gene set libraries. Clicking on an experimental condition highlights gene-sets enriched for the differentially expressed genes from the selected experiment. A search interface allows users to input gene lists and query them against over 100 000 conditions to find the top matching experiments. The tool integrates many resources for an unprecedented potential for new discoveries in systems biology and systems pharmacology. The LCB application is available at http://www.maayanlab.net/LINCS/LCB. Customized versions will be made part of the http://lincscloud.org and http://lincs.hms.harvard.edu websites

Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant- Level Meta-Analysis of Randomized Trial

Background Three phase 2b, double-blind, placebo-controlled, randomized efficacy trials have tested recombinant Adenovirus serotype-5 (rAd5)-vector preventive HIV-1 vaccines: MRKAd5 HIV-1 gag/pol/nef in Step and Phambili, and DNA/rAd5 HIV-1 env/gag/pol in HVTN505. Due to efficacy futility observed at the first interim analysis in Step and HVTN505, participants of all three studies were unblinded to their vaccination assignments during the study but continued follow–up. Rigorous meta-analysis can provide crucial information to advise the future utility of rAd5-vector vaccines. Methods We included participant-level data from all three efficacy trials, and three Phase 1–2 trials evaluating the HVTN505 vaccine regimen. We predefined two co-primary analysis cohorts for assessing the vaccine effect on HIV-1 acquisition. The modified-intention-to-treat (MITT) cohort included all randomly assigned participants HIV-1 uninfected at study entry, who received at least the first vaccine/placebo, and the Ad5 cohort included MITT participants who received at least one dose of rAd5-HIV vaccine or rAd5-placebo. Multivariable Cox regression models were used to estimate hazard ratios (HRs) of HIV-1 infection (vaccine vs. placebo) and evaluate HR variation across vaccine regimens, time since vaccination, and subgroups using interaction tests. Findings Results are similar for the MITT and Ad5 cohorts; we summarize MITT cohort results. Pooled across the efficacy trials, over all follow-up time 403 (n = 224 vaccine; n = 179 placebo) of 6266 MITT participants acquired HIV-1, with a non-significantly higher incidence in vaccine recipients (HR 1.21, 95% CI 0.99–1.48, P = 0.06). The HRs significantly differed by vaccine regimen (interaction P = 0.03; MRKAd5 HR 1.41, 95% CI 1.11–1.78, P = 0.005 vs. DNA/rAd5 HR 0.88, 95% CI 0.61–1.26, P = 0.48). Results were similar when including the Phase 1–2 trials. Exploratory analyses based on the efficacy trials supported that the MRKAd5 vaccine-increased risk was concentrated in Ad5-positive or uncircumcised men early in follow-up, and in Ad5-negative or circumcised men later. Overall, MRKAd5 vaccine-increased risk was evident across subgroups except in circumcised Ad5-negative men (HR 0.97, 95% CI 0.58−1.63, P = 0.91); there was little evidence that the DNA/rAd5 vaccine, that was tested in this subgroup, increased risk (HR 0.88, 95% CI 0.61–1.26, P = 0.48). When restricting the analysis of Step and Phambili to follow-up time before unblinding, 114 (n = 65 vaccine; n = 49 placebo) of 3770 MITT participants acquired HIV-1, with a non-significantly higher incidence in MRKAd5 vaccine recipients (HR 1.30, 95% CI 0.89–1.14, P = 0.18). Interpretation and Significance The data support increased risk of HIV-1 infection by MRKAd5 over all follow-up time, but do not support increased risk of HIV-1 infection by DNA/rAd5. This study provides a rationale for including monitoring plans enabling detection of increased susceptibility to infection in HIV-1 at-risk populations